Ewan K Cobran1, Yesenia Merino2, Beth Roach3, Sharon M Bigelow3, Paul A Godley4. 1. University of Georgia, College of Pharmacy, Department of Pharmaceutical Health Services, Outcomes, and Policy, Athens, GA. 2. University of North Carolina at Chapel Hill, Gillings School of Public Health, Department of Health Behavior, Chapel Hill, NC. 3. NavigateCancer Foundation, Apex, NC. 4. Lineberger Comprehensive Cancer Center and the Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Abstract
BACKGROUND: Navigation programs are generally characterized as providing patient-centered support and guidance intended to help patients and family members overcome barriers such as timely diagnosis resolution, patient satisfaction, coping with primary and adjuvant treatment, management of side effects, and patient engagement in the healthcare process. The aim of this study was to examine the associations between the Independent Specialty Medical Advocate (ISMA) model of patient navigation and intermediate patient health outcomes for newly diagnosed cancer patients. METHODS: A pre-post intervention study was conducted in 26 newly diagnosed cancer patients recruited from a national partnership between the LIVESTRONG Cancer Navigation Service Program and the NavigateCancer Foundation between April 2013 and December 2015. Participants received a 1-hour initial telephone consultation, and then a navigation care plan was developed for the 6-week study period. A paired t test was conducted to assess changes in intermediate health outcomes at baseline and 6 weeks after study intervention. RESULTS: The majority of study participants were males (62%), married (50%), and Caucasian (69%). Overall, there was a statistically significant reduction in anxiety at 6 weeks postintervention (mean, 2.48; SD, 0.62; P <.05) compared with baseline (mean, 2.92; SD, 0.82) and in depression at 6 weeks postintervention (mean, 2.00; SD, 0.81; P <.05) compared with baseline (mean, 2.45; SD, 0.19). CONCLUSION: The ISMA model of patient navigation appears to be associated with significant reduction in anxiety and depression. Further studies are needed to evaluate the ISMA model of patient navigation on long-term patient outcomes.
BACKGROUND: Navigation programs are generally characterized as providing patient-centered support and guidance intended to help patients and family members overcome barriers such as timely diagnosis resolution, patient satisfaction, coping with primary and adjuvant treatment, management of side effects, and patient engagement in the healthcare process. The aim of this study was to examine the associations between the Independent Specialty Medical Advocate (ISMA) model of patient navigation and intermediate patient health outcomes for newly diagnosed cancer patients. METHODS: A pre-post intervention study was conducted in 26 newly diagnosed cancer patients recruited from a national partnership between the LIVESTRONG Cancer Navigation Service Program and the NavigateCancer Foundation between April 2013 and December 2015. Participants received a 1-hour initial telephone consultation, and then a navigation care plan was developed for the 6-week study period. A paired t test was conducted to assess changes in intermediate health outcomes at baseline and 6 weeks after study intervention. RESULTS: The majority of study participants were males (62%), married (50%), and Caucasian (69%). Overall, there was a statistically significant reduction in anxiety at 6 weeks postintervention (mean, 2.48; SD, 0.62; P <.05) compared with baseline (mean, 2.92; SD, 0.82) and in depression at 6 weeks postintervention (mean, 2.00; SD, 0.81; P <.05) compared with baseline (mean, 2.45; SD, 0.19). CONCLUSION: The ISMA model of patient navigation appears to be associated with significant reduction in anxiety and depression. Further studies are needed to evaluate the ISMA model of patient navigation on long-term patient outcomes.
Authors: Pascal Jean-Pierre; Kevin Fiscella; Karen M Freund; Jack Clark; Julie Darnell; Alan Holden; Douglas Post; Steven R Patierno; Paul C Winters Journal: Cancer Date: 2010-10-04 Impact factor: 6.860
Authors: Tracy A Battaglia; Julie S Darnell; Naomi Ko; Fred Snyder; Electra D Paskett; Kristen J Wells; Elizabeth M Whitley; Jennifer J Griggs; Anand Karnad; Heather Young; Victoria Warren-Mears; Melissa A Simon; Elizabeth Calhoun Journal: Breast Cancer Res Treat Date: 2016-07-18 Impact factor: 4.872
Authors: Tracy A Battaglia; Linda Burhansstipanov; Samantha S Murrell; Andrea J Dwyer; Sarah E Caron Journal: Cancer Date: 2011-08 Impact factor: 6.860
Authors: Douglas M Post; Ann Scheck McAlearney; Gregory S Young; Jessica L Krok-Schoen; Jesse J Plascak; Electra D Paskett Journal: J Cancer Educ Date: 2015-12 Impact factor: 2.037
Authors: Gabrielle B Rocque; J Nicholas Dionne-Odom; Angela M Stover; Casey L Daniel; Andres Azuero; Chao-Hui Sylvia Huang; Stacey A Ingram; Jeffrey A Franks; Nicole E Caston; D' Ambra N Dent; Ethan M Basch; Bradford E Jackson; Doris Howell; Bryan J Weiner; Jennifer Young Pierce Journal: BMC Health Serv Res Date: 2022-04-22 Impact factor: 2.908
Authors: Ronald M Kline; Gabrielle B Rocque; Elizabeth A Rohan; Kris A Blackley; Cynthia A Cantril; Mandi L Pratt-Chapman; Howard A Burris; Lawrence N Shulman Journal: J Oncol Pract Date: 2019-09-11 Impact factor: 3.840